Prostate cancer (PCa) is the most prevalent malignancy and leading cause of mortality in men. Despite the development of various […]

There are times when we are grateful to be given just a wee snippet of what’s important in the minds […]

A recent real-world study observed that 24% of patients with advanced non–small cell lung cancer (aNSCLC) with actionable driver oncogenes […]

The MONARCH 2 trial (NCT02107703) showed the efficacy of abemaciclib, a cyclin-dependent kinase 4 & 6 inhibitor (CDK4/6i), in combination […]

Prior work from the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) consortium (ICECaP-1) demonstrated that metastasis-free survival (MFS) […]

The US Food and Drug Administration (FDA) approved elacestrant for the treatment of postmenopausal women or adult men with estrogen […]

As a newly identified subtype of HER2-negative tumors associated with a less favorable prognosis, it remains crucial to evaluate potential […]

Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available […]

Patients with lung cancer who have EGFR exon 20 mutations typically have a poor prognosis. Other than chemotherapy, no other […]

There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients […]